Morgan Stanley Reiterates Overweight Rating On MetLIfe (MET)

In a recent report, Morgan Stanley has reiterated an overweight rating on MetLife MET after solid results, impressive sales and little impact from Japan in 1Q. In the report, Morgan Stanley said, "MetLife remains our highest conviction Overweight rated stock in the life and annuity universe. We believe a combination of accretion from the Alico transaction, likely capital management, and solid growth positions the company to achieve meaningful ROE improvement which is not reflected in the stock price." MetLife closed yesterday at $46.15.